Our current pipeline includes NM-137 for the acute rescue of obstructive hypertrophic cardiomyopathy (HOCM) and atrial fibrillations (AF), NM-411 for pulmonary hypertension (PHT) and NM-911 for infectious diseases including Covid-19. We are currently generating data that not only provide proof of concept but also significantly reduced off target effects while minimizing other general toxicities. True to our mission, we have a rigorous selection process for both medicines and disease indications enabling us to provide the best value for our patients.
Nova Mentis Pharma 